1163 related articles for article (PubMed ID: 25971297)
21. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
22. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
Wolin EM
Cancer Lett; 2013 Jul; 335(1):1-8. PubMed ID: 23419523
[TBL] [Abstract][Full Text] [Related]
23. The anti-esophageal cancer cell activity by a novel tyrosine/phosphoinositide kinase inhibitor PP121.
Peng Y; Zhou Y; Cheng L; Hu D; Zhou X; Wang Z; Xie C; Zhou F
Biochem Biophys Res Commun; 2015 Sep; 465(1):137-44. PubMed ID: 26235881
[TBL] [Abstract][Full Text] [Related]
24. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
[TBL] [Abstract][Full Text] [Related]
25. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
[TBL] [Abstract][Full Text] [Related]
26. Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.
Pawaskar DK; Straubinger RM; Fetterly GJ; Hylander BH; Repasky EA; Ma WW; Jusko WJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1231-40. PubMed ID: 23455452
[TBL] [Abstract][Full Text] [Related]
27. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
28. mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors.
Lewis CS; Elnakat Thomas H; Orr-Asman MA; Green LC; Boody RE; Matiash K; Karve A; Hisada YM; Davis HW; Qi X; Mercer CA; Lucas FV; Aronow BJ; Mackman N; Versteeg HH; Bogdanov VY
J Thromb Haemost; 2019 Jan; 17(1):169-182. PubMed ID: 30472780
[TBL] [Abstract][Full Text] [Related]
29. Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cells by a novel FAK inhibitor, PH11.
Dao P; Smith N; Scott-Algara D; Garbay C; Herbeuval JP; Chen H
Cancer Lett; 2015 Apr; 360(1):48-59. PubMed ID: 25684663
[TBL] [Abstract][Full Text] [Related]
30. Current understanding of the molecular biology of pancreatic neuroendocrine tumors.
Zhang J; Francois R; Iyer R; Seshadri M; Zajac-Kaye M; Hochwald SN
J Natl Cancer Inst; 2013 Jul; 105(14):1005-17. PubMed ID: 23840053
[TBL] [Abstract][Full Text] [Related]
31. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M
Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739
[TBL] [Abstract][Full Text] [Related]
32. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
Kanteti R; Mirzapoiazova T; Riehm JJ; Dhanasingh I; Mambetsariev B; Wang J; Kulkarni P; Kaushik G; Seshacharyulu P; Ponnusamy MP; Kindler HL; Nasser MW; Batra SK; Salgia R
Cancer Biol Ther; 2018 Apr; 19(4):316-327. PubMed ID: 29303405
[TBL] [Abstract][Full Text] [Related]
33. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
[TBL] [Abstract][Full Text] [Related]
34. mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment.
Orr-Asman MA; Chu Z; Jiang M; Worley M; LaSance K; Koch SE; Carreira VS; Dahche HM; Plas DR; Komurov K; Qi X; Mercer CA; Anthony LB; Rubinstein J; Thomas HE
Mol Cancer Ther; 2017 Nov; 16(11):2432-2441. PubMed ID: 28864682
[TBL] [Abstract][Full Text] [Related]
35. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
36. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
Zitzmann K; Rüden Jv; Brand S; Göke B; Lichtl J; Spöttl G; Auernhammer CJ
Cancer Lett; 2010 Sep; 295(1):100-9. PubMed ID: 20356670
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F
Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875
[TBL] [Abstract][Full Text] [Related]
38. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
39. MEN1 Degradation Induced by Neddylation and the CUL4B-DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression.
Xu J; Ye Z; Zhuo Q; Gao H; Qin Y; Lou X; Zhang W; Wang F; Wang Y; Jing D; Fan G; Zhang Y; Chen X; Chen J; Xu X; Yu X; Ji S
Cancer Res; 2023 Jul; 83(13):2226-2247. PubMed ID: 36939378
[TBL] [Abstract][Full Text] [Related]
40. Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells.
Spampatti M; Vlotides G; Spöttl G; Maurer J; Göke B; Auernhammer CJ
World J Gastroenterol; 2014 Aug; 20(29):10038-49. PubMed ID: 25110431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]